GLP-1 weight-loss therapies and breast cancer risk are examined in an engaging article that reviews observational evidence, expert caveats, and upcoming research directions.
Key Takeaways
- Large observational study found GLP-1 users had about 30% lower breast cancer incidence
- Researchers cautioned the association is not proof of causation and needs testing
- Clinical trials are being planned to test GLP-1 drugs for breast cancer prevention